Aurinia Pharmaceuticals Inc (AUPH) Given Consensus Rating of “Buy” by Analysts

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has been assigned a consensus rating of “Buy” from the ten analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.39.

Several research firms recently commented on AUPH. Seaport Global Securities reiterated a “buy” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th. Vetr upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $7.35 target price on the stock in a research report on Tuesday, September 19th. Leerink Swann lifted their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Cantor Fitzgerald reiterated a “buy” rating and set a $14.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, October 23rd. Finally, Canaccord Genuity set a $11.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 24th.

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at $5.26 on Friday. Aurinia Pharmaceuticals has a one year low of $2.30 and a one year high of $10.54. The firm has a market cap of $435.82, a P/E ratio of -4.35 and a beta of 2.34.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. The company’s revenue was up .0% on a year-over-year basis. equities research analysts forecast that Aurinia Pharmaceuticals will post -1.05 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Aurinia Pharmaceuticals by 0.3% in the 2nd quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock valued at $35,969,000 after acquiring an additional 19,200 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Aurinia Pharmaceuticals by 357.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock valued at $5,373,000 after acquiring an additional 684,816 shares in the last quarter. Alyeska Investment Group L.P. increased its stake in shares of Aurinia Pharmaceuticals by 1.8% in the 3rd quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock valued at $4,273,000 after acquiring an additional 12,171 shares in the last quarter. Balyasny Asset Management LLC increased its stake in shares of Aurinia Pharmaceuticals by 66.7% in the 2nd quarter. Balyasny Asset Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $3,065,000 after acquiring an additional 200,000 shares in the last quarter. Finally, AWM Investment Company Inc. increased its stake in shares of Aurinia Pharmaceuticals by 17.5% in the 2nd quarter. AWM Investment Company Inc. now owns 352,500 shares of the biotechnology company’s stock valued at $2,161,000 after acquiring an additional 52,500 shares in the last quarter. Institutional investors own 28.13% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aurinia Pharmaceuticals Inc (AUPH) Given Consensus Rating of “Buy” by Analysts” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/03/aurinia-pharmaceuticals-inc-auph-given-consensus-rating-of-buy-by-analysts.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply